# A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

> **NCT01259297** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2336 (actual)

## Conditions studied

- Cardiovascular Events

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Amlodipine
- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Placebo for Aliskiren
- **DRUG:** Placebo for Amlodipine
- **DRUG:** Placebo for Hydrochlorothiazide (HCTZ)

## Key facts

- **NCT ID:** NCT01259297
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 2336 (ACTUAL)
- **Why stopped:** Terminated early in agreement with Health Authorities for feasibility reasons
- **Last updated:** 2014-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01259297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01259297, "A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01259297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*